Completed PHASE1 INTERVENTIONAL NCT00252889

Doxil Topotecan Doublet Cancer Study

GSK - Doublet: A Phase I Study of Pegylated Liposomal Doxorubicin (Doxil) and Weekly Intravenous Topotecan in Patients With Advanced Solid Tumors

Sponsor: Christiana Care Health Services

Conditions Esophageal Cancer Gastric Cancer Head and Neck Cancer Pancreatic Cancer Small Cell Lung Cancer

Interventions Topotecan and pegylated doxorubicin

Updated 5 times since 2017 Last updated: Jan 26, 2009 Started: May 31, 2004 Primary completion: Mar 31, 2006 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Esophageal Cancer and Gastric Cancer, this trial is completed. The trial is conducted by Christiana Care Health Services and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Christiana Care Health Services
GlaxoSmithKline
Johnson & Johnson

Data source: Christiana Care Health Services

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Newark, United States